Soft tissue neoplasms, also known as abnormal growths arise in connective tissues, such as muscles, fat, blood vessels, nerves, and fibrous tissues. They may be malignant (soft tissue sarcomas) or benign (non-cancerous). Rare yet aggressive, malignant tumors like liposarcoma and leiomyosarcoma can spread to other organs. Chemical carcinogens, radiation exposure, and genetic mutations are risk factors. Painless tumors, edema, or limited mobility are possible symptoms. Treatment options include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy, depending on the type and stage of the tumor. Early diagnosis lowers problems and improves results. Moreover, the rising prevalence is anticipated to positively impact the pipeline landscape for soft tissue neoplasms.
The Soft Tissue Neoplasms Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into soft tissue neoplasms therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Soft Tissue Neoplasms. The soft tissue neoplasms report assessment includes the analysis of over 50 pipeline drugs and 25+ companies. The soft tissue neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with soft tissue neoplasms treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to soft tissue neoplasms.
The management of soft tissue neoplasms is based on tumor type, size, location, and malignancy. The main treatment for localized tumors is surgical excision, which guarantees total removal with distinct margins. Before surgery, radiation therapy is used to reduce tumor size. Whereas, after surgery, it is used to eradicate any remaining cancer cells. For cases that are progressed or metastatic, chemotherapy and targeted treatments such as tyrosine kinase inhibitors (TKIs) work well. Immunotherapy is a new treatment for several sarcoma subtypes. Routine monitoring that uses imaging and biopsies enables timely intervention and prevention from recurrence prevention.
The high bioavailability, tumor-penetration capabilities, and tailored effect on cancer pathways make small molecules useful in the treatment of soft tissue neoplasms. These medications, such as tyrosine kinase inhibitors (TKIs), stop tumor growth by blocking signaling pathways and angiogenesis that are necessary for the spread of cancer. Treatment is more convenient because they can be taken orally. Additionally, tiny molecules have fewer long-term negative effects and adjustable dosing due to their shorter half-life. Their ability to effectively target mutations makes them a crucial choice in precision oncology. Further, the rising focus on soft tissue neoplasms emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Sarcomas and other soft tissue neoplasms make up around 1% of all malignant tumors, making them comparatively uncommon. The typical diagnosis age is 62 years, and there are about 13,520 new cases identified in the United States each year. Liposarcoma and undifferentiated pleomorphic sarcoma are the most prevalent varieties. Age-specific incidence rates peak among those 65–74 years old. The incidence varies between 15 and 35 per million people worldwide, underscoring the need for more study and education on these aggressive tumors and treatment options.
This section of the report covers the analysis of soft tissue neoplasms drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of soft tissue neoplasm drugs undergoing clinical development.
The drug molecule categories covered under soft tissue neoplasms pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The soft tissue neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for soft tissue neoplasms.
The EMR report for the soft tissue neoplasms drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed soft tissue neoplasms therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in soft tissue neoplasms clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Eli Lilly and Company, the objective of this multicenter clinical trial is to investigate the efficacy and safety of the LOXO-292, a soft tissue neoplasms drug candidate. The study is under Phase I/II clinical development.
Daiichi Sankyo Co., Ltd. is conducting a study aimed at examining the efficacy of the investigational drug pexidartinib for the treatment of soft tissue neoplasms. The study is under Phase II clinical development.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The soft tissue neoplasms drug report provides a strategic overview of the latest and future landscape of treatments for soft tissue neoplasms. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within soft tissue neoplasms pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share